Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged > 80 years

Clinical Lung Cancer

Volumn 8, Issue 5, 2007, Pages 331-334

  Breen, David ^a,b   Barlési, Fabrice ^a   Zemerli, Myriam ^a   Doddoli, Christophe ^a   Torre, Jean Philippe ^c   Thomas, Pascal ^a   Astoul, Philippe ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b ST JAMES S HOSPITAL   (Ireland)

^c TIMONE HOSPITAL   (France)

Author keywords

Charlson comorbidity index; Hazard ratio

Indexed keywords

AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVIEW; TREATMENT RESPONSE;

EID: 34248207626     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.013     Document Type: Article

References (18)

1. Makrantonakis PD, Galani E, Harper PG. Non-small cell lung cancer in the elderly. Oncologist 2004; 9:556-560.
2. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung cancer. Thorax 1996; 51:564-568.
3. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59:602-607.
4. Benson AB III, Pregler JP, Bean JA, et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 1991; 9:2067-2075.
5. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-2536.
6. Firat S, Bousamra M, Gore E, et al. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol 2002; 52:1047-1057.
7. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-181.
8. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98:779-788.
9. Weinmann M, Jeremic B, Toomes H, et al. Treatment of lung cancer in the elderly. Part I; non-small cell lung cancer. Lung Cancer 2003; 39:223-253.
10. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23:3123-3137.
11. Jaklitsch MT, Bueno R, Swanson SJ, et al. New surgical options for elderly lung cancer patients. Chest 1999; 116(suppl 6):480s-485s.
12. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86:1867-1876.
13. Charlson M, Pompei P, Ales K. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383.
14. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 335:1020-1022.
15. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003; 97:3133-3275.
16. Ouelette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004; 8:1061-1067.
17. Lecaer H, Gimenez C, Fournel P, et al. A multicenter phase II study of docetaxel or docetaxel/gemcitabine weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (GFPC 0202). J Clin Oncol 2005; 23:657s (Abstract #7150).
18. LeCaer H, Delhoume JY, Thomas PA, et al. Multicenter phase II trial of carbopUtin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902. Clin Lung Cancer 2005; 7:114-120.